Full-Time

Scientist II or Senior Scientist

Immunology

Posted on 5/31/2024

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops small molecule protein degraders for diseases

Biotechnology

Mid, Senior

Belmont, MA, USA

Requirements
  • Extensive hands-on experience with isolation and culture of primary immune cells
  • Experience with developing flow multi-plex panels to identify immune subsets
  • Familiarity with immune cellular assays such as M1 macrophage polarization, B cell differentiation, and Ig class switching assays
  • Ability to summarize literature findings to support scientific and technical strategies
  • Experience with software such as flowjo and graphpad prism
  • Attention to detail and proven track record in handling, analyzing, and recording experimental data
Responsibilities
  • Independently design and execute on cellular assay strategy to support indication selection and expansion of lead optimization program
  • Develop cytokine release, proliferation, and differentiation immune cell assays using healthy and diseased samples, with a focus on B cells and monocytes
  • Profile innate and adaptive immune cells by flow cytometry multi-plex assays
  • Independently analyze and present findings at group and project team meetings

Kymera Therapeutics is at the forefront of utilizing its proprietary Pegasus platform to develop small molecule protein degraders, targeting specific disease-causing proteins in critical areas like immunology-inflammation and oncology. This offers a dynamic workplace with a focus on cutting-edge technology and treatments that could drastically improve patient outcomes in significant disease domains. The company's commitment to advancing medical science and its technical proficiency provides a stimulating environment for professionals passionate about making a tangible impact on healthcare.

Company Stage

IPO

Total Funding

$879M

Headquarters

Watertown, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

7%

2 year growth

30%
INACTIVE